Moncyte Health's test evaluates biological differences in how cholesterol is transported and processed in cells, which can ...

The firm recorded Q4 oncology revenues of $4.06 billion compared to $3.19 billion in the same period last year.

The proposal, purported to save $83 billion over a decade, is a "dagger in the heart of all patient advocacy nonprofits," said the head of a cancer patient support group.

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begin in 2028.

Researchers will use a lipidomic biomarker test to select patients with a poor prognosis who may benefit from an investigational combination therapy.

The FDA has offered positive feedback on possible paths forward for accelerated or traditional approval of FLT201 using data from a single-arm study.

The regulator approved the indication based on data showing Kisqali with an aromatase inhibitor improved invasive disease-free survival versus just an aromatase inhibitor.

The committee recommended the new formulation in two EGFR-mutated advanced NSCLC settings, for which intravenous Rybrevant is already available.

The firm will begin testing a second dose cohort with AMT-191 after receiving a positive recommendation from a data monitoring committee.

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

NEW YORK – Fractyl Health on Friday said it intends to initiate a first-in-human trial of a gene therapy it's developing to treat type 2 diabetes, RJVA-001, in the first half of 2025. Burlington, ...